Single Molecule Protein Sequencing Platforms Will Drive Long Term Proteomics Demand Narrative

Catalysts

About Quantum-Si

Quantum-Si develops single molecule protein sequencing platforms and consumables that enable advanced proteomics research across academic, biopharma and government labs.

What are the underlying business or industry changes driving this perspective?

• Expansion of the installed base through flexible placement and acquisition models is building an annuity-like stream of consumables demand. This can compound revenue growth as capital budgets normalize and usage per instrument scales.
• Successful prototype sequencing runs on the Proteus system and a defined 2026 launch path position Quantum-Si to tap into the rapid shift toward next generation proteomics tools. This could materially lift instrument revenue and improve overall gross margin as higher value systems enter the mix.
• Advances such as the version 4 sequencing kit, expanded barcoding and the forthcoming low input library prep kit are broadening addressable applications and sample types. This should increase average consumables spend per customer and support higher recurring revenue visibility.
• Deep proprietary datasets from the amino acid recognizer program combined with artificial intelligence tools can accelerate progress toward broader proteome coverage. This can enhance product differentiation and pricing power that can support better long-term net margins.
• Tight cost controls, lease rationalization and a cash balance above $230 million provide runway to invest through current capital market headwinds. This allows the company to convert growing scientific validation and multi omics partnership opportunities into future earnings leverage when revenues scale.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Quantum-Si's revenue will grow by 137.7% annually over the next 3 years.
• Analysts are not forecasting that Quantum-Si will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Quantum-Si's profit margin will increase from -3678.0% to the average US Life Sciences industry of 15.7% in 3 years.
• If Quantum-Si's profit margin were to converge on the industry average, you could expect earnings to reach $6.7 million (and earnings per share of $0.03) by about December 2028, up from $-116.8 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 132.7x on those 2028 earnings, up from -2.3x today. This future PE is greater than the current PE for the US Life Sciences industry at 35.2x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.76%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Persistent capital market and NIH funding headwinds in academic research could structurally limit instrument purchases and slow installed base growth, constraining long-term revenue expansion and delaying operating leverage in earnings.
• The Proteus platform faces an unusually aggressive development and launch schedule. Any delays in scaling prototypes to manufacturable systems or in optimizing sequencing chemistry could push out commercialization milestones, dampening future revenue and margin improvement.
• Heavy ongoing investment in R&D and commercialization, combined with adjusted operating expenses near $96 million and modest current revenue, increases the risk that cash burn stays elevated for longer than expected. This could pressure net margins and potentially require dilutive capital raises that undermine share price appreciation.
• Margin volatility driven by instrument versus consumables mix, legacy inventory adjustments and non cash lease related charges suggests that achieving sustainably high gross margins may take longer than planned. This may limit the improvement in gross profit and delay a path to positive earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $2.68 for Quantum-Si based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $4.05, and the most bearish reporting a price target of just $1.5.
  
• In order for you to agree with the analysts, you'd need to believe that by 2028, revenues will be $42.7 million, earnings will come to $6.7 million, and it would be trading on a PE ratio of 132.7x, assuming you use a discount rate of 7.8%.
  
• Given the current share price of $1.23, the analyst price target of $2.68 is 54.2% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.